While lawyers for Merck & Co. and Upsher-Smith Laboratories wait to find out whether the U.S. Supreme Court will hear a crucial challenge over a so-called pay-for-delay deal involving the potassium supplement K-Dur, other pharma companies have been busy trying to convince judges to put their own cases on ice. Mostly, they’ve succeeded.
The latest litigation freeze came when U.S. District Judge Joel Pisano in Trenton, New Jersey, agreed to stay a sprawling consolidated antitrust case against Pfizer Inc.’s Wyeth unit and generic drug manufacturer Teva Pharmaceuticals Industries.
